citalopram

1
Reactions 826 - 4 Nov 2000 S Citalopram First report of Parkinson’s disease in an elderly patient: case report Citalopram therapy for major depression was associated with the onset of Parkinson’s disease in a 68-year-old woman. The woman started treatment with citalopram [‘Cipramil’] 20 mg/day when she was assessed for massive suicidal thoughts and depression. During the previous year, she had also experienced episodes of anxiety and sleeplessness. Seven days after starting citalopram, she was hospitalised with severe parkinsonian symptoms including rigidity, bradykinesia and tremor. The next day, her symptoms worsened: she was not able to walk or turn over in bed without help, her facial movements were hypokinetic and her handwriting was illegible. Two days later, the dosage of citalopram was increased to 40 mg/day and her parkinsonian symptoms worsened. The dosage of citalopram was reduced the next day [dosage not stated]. After a further 2 days’ therapy, citalopram was discontinued and antidepressant therapy was continued with nortriptyline; however, her parkinsonian symptoms persisted. Test doses of levodopa and benserazide were administered 10 days after citalopram was stopped. The woman’s parkinsonian symptoms considerably improved and treatment with these agents was continued. Subsequently, cabergoline was added to her regimen and her parkinsonian symptoms resolved. Three weeks later, her depression had remitted. 44 days after admission to hospital, she was discharged receiving nortriptyline therapy. A final diagnosis of Parkinson’s disease was made. Author comment: ‘Although we cannot exclude that, in this patient, the Parkinson’s disease onset had been a coincidence, we suggest that, in our case, a sub-threshold dopaminergic lesion was already present when citalopram was started, and that the increase of serotoninergic inhibition of dopaminergic function lead to the clinical de novo manifestation of Parkinson’s disease.’ Stadtland C, et al. De Novo onset of Parkinson’s disease after antidepressant treatment with citalopram. Pharmacopsychiatry 33: 194-195, Sep 2000 - Germany 800843981 » Editorial comment: A search of AdisBase and Medline did not reveal any previous case reports of Parkinson’s disease associated with citalopram. 1 Reactions 4 Nov 2000 No. 826 0114-9954/10/0826-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: phamduong

Post on 18-Mar-2017

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Citalopram

Reactions 826 - 4 Nov 2000

★ SCitalopram

First report of Parkinson’s disease in an elderlypatient: case report

Citalopram therapy for major depression was associatedwith the onset of Parkinson’s disease in a 68-year-old woman.

The woman started treatment with citalopram [‘Cipramil’]20 mg/day when she was assessed for massive suicidalthoughts and depression. During the previous year, she hadalso experienced episodes of anxiety and sleeplessness. Sevendays after starting citalopram, she was hospitalised with severeparkinsonian symptoms including rigidity, bradykinesia andtremor. The next day, her symptoms worsened: she was notable to walk or turn over in bed without help, her facialmovements were hypokinetic and her handwriting wasillegible. Two days later, the dosage of citalopram wasincreased to 40 mg/day and her parkinsonian symptomsworsened. The dosage of citalopram was reduced the next day[dosage not stated]. After a further 2 days’ therapy, citalopramwas discontinued and antidepressant therapy was continuedwith nortriptyline; however, her parkinsonian symptomspersisted.

Test doses of levodopa and benserazide were administered10 days after citalopram was stopped. The woman’sparkinsonian symptoms considerably improved and treatmentwith these agents was continued. Subsequently, cabergolinewas added to her regimen and her parkinsonian symptomsresolved. Three weeks later, her depression had remitted. 44days after admission to hospital, she was discharged receivingnortriptyline therapy. A final diagnosis of Parkinson’s diseasewas made.

Author comment: ‘Although we cannot exclude that, in thispatient, the Parkinson’s disease onset had been a coincidence,we suggest that, in our case, a sub-threshold dopaminergiclesion was already present when citalopram was started, andthat the increase of serotoninergic inhibition of dopaminergicfunction lead to the clinical de novo manifestation ofParkinson’s disease.’Stadtland C, et al. De Novo onset of Parkinson’s disease after antidepressanttreatment with citalopram. Pharmacopsychiatry 33: 194-195, Sep 2000 -Germany 800843981

» Editorial comment: A search of AdisBase and Medline didnot reveal any previous case reports of Parkinson’s diseaseassociated with citalopram.

1

Reactions 4 Nov 2000 No. 8260114-9954/10/0826-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved